AWKN:NEO; AWKNF:OTCQB

Awakn Life Sciences Corp.

Awakn Life Sciences Corp. is a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat substance and behavioral addictions. Awakn has a near-term focus on Alcohol Use Disorder (AUD), a condition affecting 400 million people globally for which the current standard of care is inadequate. Our goal is to provide effective therapeutics to addiction sufferers in desperate need and our strategy is focused on commercializing our R&D pipeline across multiple channels.
AWKN:NEO AWKNF:OTCQB

Expert Comments:

read more >
One analyst says this healthcare co. has the opportunity to generate attractive CAPEX-light, high margin SaaS-like recurring revenues, which investors are currently getting for free, after the biotech firm entered the US market for alcohol addiction treatment through off-label licensing deals with a network of treatment clinics.
read more >
Awakn Life Sciences Corp.'s rating went to an Immediate Speculative Buy after it received substantial funding from the UK government. Expert Clive Maund shares his thoughts on the development.
read more >
A revenue-generating junior biotech company based in the U.K. has become the first public company to be approved for a government grant to fund most of a Phase 3 study exploring the use of psychedelics to treat Alcohol Use Disorder. It could be a catalyst for the share price.
read more >
Psychedelic-assisted therapy has shown in a clinical trial that it can help patients with Alcohol Use Disorder (AUD) or alcoholism. One company hopes to bring its treatments to clinics throughout Europe and become the go-to standard of care for AUD.
read more >
One healthcare co. is currently rated a Buy and is making a push for a share of the $17.5-billion addiction treatment industry after a recent study showed its psychedelic-assisted psychotherapy treatment showed a significant decrease in alcohol use, noted a Maxim Group equity research report.
read more >
One healthcare company with upcoming catalysts wants to take a share of the CA$6-billion alcoholism treatment market with its proprietary psychedelic-assisted psychotherapy treatments.
read more >
It is difficult to get three people to agree on anything, let alone three investment analysts. But that is precisely the case with one junior biotech company that has shown in a clinical trial that its ketamine-assisted therapy for alcohol use disorder (AUD) is three times more effective than the current standard of care.
read more >

Patrick Trucchio, H.C. Wainwright & Co.

(6/30/22)
"Awakn Life Sciences Corp.'s key programs are on track. . .a follow-on behavioral study investigating ketamine in gambling disorder has been initiated with completion expected in H2/22. . . Awakn announced successful completion of hit to lead drug discovery program for new chemical entities and expects to initiate a lead optimization program in H2/22."

Patrick Trucchio, H.C. Wainwright & Co.

(5/2/22)
"Awakn Life Sciences Corp. remains focused on initiating a Phase 2b trial to evaluate MDMA-assisted therapy in alcohol use disorder, a program that we believe could emerge as the company's most valuable and that remains underappreciated by investors. . .the ketamine for reduction of alcoholic relapse (i.e., KARE) program is on track to advance to Phase 3 in H2/22."

Andrew Partheniou, Stifel

(3/31/22)
"We highlight Awakn Life Sciences Corp. as a pure play psychedelic company focused on treating addiction, with a world-renowned management team including famed Professor David Nutt, a differentiated clinic strategy leveraging the only clinical trial-backed ketamine therapy protocol for alcohol use disorder (AUD) and a derisked drug development pathway with its lead candidate MDMA for AUD currently in Phase 2. With the company's enterprise value below $50M, we believe shares offer an attractive risk-reward profile. . we initiate with a Speculative Buy."

Patrick Trucchio, H.C. Wainwright & Co.

(2/1/22)
"Awakn Life Sciences Corp. is a neuro-focused biotech company comprising research and development which is focused on advancing ketamine- and MDMA-assisted therapies, as well as new chemical entities to treat alcohol and behavioral addictions. . .we find the company's shares attractive at current levels and initiate with a Buy rating."

headshot of Jason McCarthy

Jason McCarthy, Maxim Group

(9/1/21)
"We initiate coverage on Awakn Life Sciences Corp. with a Buy rating. . .the company is unique in psychedelics, integrating clinics with development of both traditional psychedelics and new chemical entities and creating synergies for both drug development and commercial launch. The importance of having both, in our view, is not fully valued at the current approximately $35M market cap."

Experts Following This Company

Clive Maund – CliveMaund.com
headshot of Jason McCarthy
Jason McCarthy, Analyst – Maxim Group
Andrew Partheniou – Stifel
Matthew Pepler, Analyst – Canaccord Genuity
Patrick Trucchio, Analyst – H.C. Wainwright & Co.

Company News 

8/15/2022 –  Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

7/20/2022 – Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs

7/15/2022 – Awakn Life Sciences Provides a Business and Corporate Update

7/5/2022 – Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Significant Market Opportunity: Alcohol Use Disorder treatment industry is large ($35bn US alone) but underperforming with low post treatment abstinence rates
 
Late Clinical Stage Lead Program: Successful phase IIb for Alcohol Use Disorder, achieving 86% abstinence for 6 months post treatment
 
Deep Pipeline Already Generating Revenue: Multiple opportunities for value creation through deep R&D pipeline and already generating revenue Awakn Clinics in the Europe
catalyst Calendar
Q3
2022
R&D: Progress lead program into Phase III; securing grant from UK state for 66% of costs of phase II
Q3
2022
Commercialisation: Enter North American market in Q4 ’22 through out-licencing agreements to 3rd par
Q3
2022
Capital Markets: Targeted up list to Nasdaq in 2023
Awakn Life Sciences Corp. Content